Prothena Corporation PLC at Stifel CNS Days (Virtual) Transcript
Thanks very much, everybody. It's my pleasure to be moderating a panel with Gene Kinney, President and CEO of Prothena. He is live our protein. I viewed live for an AD/PD, so very generous of your time to join us remotely, Gene. I really appreciate it.
And maybe just quickly complement an overview Prothena R&D portfolio, key events coming up, and then of course, we will probably spend most of the time talking about beta amyloid, but I will turn it over to you briefly the stage.
Sounds good. So first of all, Paul, thank you for having us. Really enjoy this meeting and enjoy having the opportunity to speak with you.
So, yeah, so for those of you that don't know Prothena all that well, our focus is really on intervening in proteins that have become dysregulated and contribute to disease. So obviously that takes us into a big area of central nervous system disorders. You can think about Alzheimer's disease and the role of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |